SCHEMBL25032440

SCHEMBL25032440

C#CCNc1ccc(P(C)(C)=O)cc1C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APEX1 P27695 1/20 0.38
▸ KMT2A Q03164 6/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ MAPT P10636 6/20 0.34
▸ MEN1 O00255 5/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ PTPN1 P18031 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ PTPRC P08575 1/20 0.34
▸ PTPN2 P17706 1/20 0.34
▸ PTPRA P18433 1/20 0.34
▸ PTPRB P23467 1/20 0.34
▸ PTPRE P23469 1/20 0.34
▸ PTPN6 P29350 1/20 0.34
▸ LTC4S Q16873 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ GFER P55789 1/20 0.34
▸ LIPC P11150 1/20 0.34
▸ LIPG Q9Y5X9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30184577 0.87 KDM4E (0.37) ALDH1A1KDM4EGAAPKMALOX15
SCHEMBL29212322 0.87 KDM4E (0.37) ALDH1A1KDM4EGAAPKMALOX15
SCHEMBL30184479 0.85 ADRA1D (0.33) ALDH1A1
SCHEMBL25033592 0.84 MAOB (0.37) ALDH1A1KDM4EHTTGAAPKM
SCHEMBL25032412 0.82 — —
SCHEMBL29212499 0.82 P2RX7 (0.37) KMT2AMAPTMEN1KDM4ERAB9A
SCHEMBL30184615 0.81 HPGD (0.41) ALDH1A1KDM4EHSD17B10GAAPKM
SCHEMBL29212430 0.81 HPGD (0.41) ALDH1A1KDM4EHSD17B10GAAPKM
SCHEMBL25033567 0.79 MCHR1 (0.33) LMNARAB9A
SCHEMBL25033427 0.78 MAOA (0.35) MAPTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
EP-4384510-A1 COMPOUNDS TARGETING MUTANT OF P53 Jacobio Pharmaceuticals Co., Ltd. (CN) 2024-06-19 — — EP disclosed
CN-117813295-A Compounds targeting p53 mutants 北京加科思新药研发有限公司 2024-04-02 — — CN disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 — — WO disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 APEX1 602/4885KMT2A 3880/4885ALDH1A1 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback